Zyrova ASP 75 Capsule is a combination medication containing Rosuvastatin 10 mg and Aspirin 75 mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and a history of or risk for atherosclerotic cardiovascular disease (ASCVD). Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thereby decreasing platelet aggregation and thrombus formation. The combined action of these agents helps in reducing the risk of myocardial infarction, stroke, and other cardiovascular events in high-risk individuals. Zyrova ASP 75 Capsule is typically prescribed as part of a comprehensive cardiovascular risk management plan including lifestyle modification. Caution is advised in patients with active bleeding, peptic ulcer disease, or hypersensitivity to aspirin or statins. Liver function tests and renal function should be monitored periodically during therapy. This combination therapy offers a synergistic approach to lipid lowering and antithrombotic prophylaxis, improving patient compliance by reducing pill burden. Use under medical supervision is recommended to optimize therapeutic outcomes and minimize adverse effects.